Patents by Inventor Fabienne Vernejoul
Fabienne Vernejoul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165242Abstract: The present invention provides a Pro-cyclic dinucleotide (Pro-CDN) comprising a STING agonist cyclic dinucleotide which is coupled to a linker system. The Pro-CDNs of the present invention can be metabolized at a targeted site into CDNs and exert their full immunomodulatory effects at said targeted site. The present invention also provides conjugates wherein a Pro-CDN is conjugated to a Biologically Active Molecule (BAM) such as e.g. a cytotoxic molecule, a lipid, a protein, a peptide, a nucleic acid, a sugar or a PRR ligand. The invention provides also methods related to the use of such compounds to perform their activities at their targeted sites, to exert cytotoxic, cytostatic or immunomodulatory effects, to treat or to prevent diseases such as cancers, immunological disorders or infections.Type: ApplicationFiled: July 26, 2023Publication date: May 23, 2024Inventors: Thierry LIOUX, Fabienne VERNEJOUL, Cédric BOULARAN, Michèle TIRABY
-
Patent number: 11730817Abstract: The present invention provides a Pro-cyclic dinucleotide (Pro-CDN) comprising a STING agonist cyclic dinucleotide which is coupled to a linker system. The Pro-CDNs of the present invention can be metabolized at a targeted site into CDNs and exert their full immunomodulatory effects at said targeted site. The present invention also provides conjugates wherein a Pro-CDN is conjugated to a Biologically Active Molecule (BAM) such as e.g. a cytotoxic molecule, a lipid, a protein, a peptide, a nucleic acid, a sugar or a PRR ligand. The invention provides also methods related to the use of such compounds to perform their activities at their targeted sites, to exert cytotoxic, cytostatic or immunomodulatory effects, to treat or to prevent diseases such as cancers, immunological disorders or infections.Type: GrantFiled: December 28, 2018Date of Patent: August 22, 2023Assignee: INVIVOGENInventors: Thierry Lioux, Fabienne Vernejoul, Cédric Boularan, Michèle Tiraby
-
Patent number: 11667664Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: GrantFiled: July 1, 2021Date of Patent: June 6, 2023Assignee: KAYLA THERAPEUTICSInventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
-
Publication number: 20230116913Abstract: The present invention provides a Pro-cyclic dinucleotide (Pro-CDN) comprising a STING agonist cyclic dinucleotide which is coupled to a linker system. The Pro-CDNs of the present invention can be metabolized at a targeted site into CDNs and exert their full immunomodulatory effects at said targeted site. The present invention also provides conjugates wherein a Pro-CDN is conjugated to a Biologically Active Molecule (BAM) such as e.g. a cytotoxic molecule, a lipid, a protein, a peptide, a nucleic acid, a sugar or a PRR ligand. The invention provides also methods related to the use of such compounds to perform their activities at their targeted sites, to exert cytotoxic, cytostatic or immunomodulatory effects, to treat or to prevent diseases such as cancers, immunological disorders or infections.Type: ApplicationFiled: December 28, 2018Publication date: April 13, 2023Inventors: Thierry LIOUX, Fabienne VERNEJOUL, Cédric BOULARAN, Michèle TIRABY
-
Publication number: 20220339287Abstract: The present invention provides a Pro-cyclic dinucleotide (Pro-CDN) comprising a STING agonist cyclic dinucleotide which is coupled to a linker system. The Pro-CDNs of the present invention can be metabolized at a targeted site into CDNs and exert their full immunomodulatory effects at said targeted site. The present invention also provides conjugates wherein a Pro-CDN is conjugated to a Biologically Active Molecule (BAM) such as e.g. a cytotoxic molecule, a lipid, a protein, a peptide, a nucleic acid, a sugar or a PRR ligand. The invention provides also methods related to the use of such compounds to perform their activities at their targeted sites, to exert cytotoxic, cytostatic or immunomodulatory effects, to treat or to prevent diseases such as cancers, immunological disorders or infections.Type: ApplicationFiled: December 28, 2018Publication date: October 27, 2022Inventors: Thierry LIOUX, Fabienne VERNEJOUL, Cédric BOULARAN, Michèle TIRABY
-
Publication number: 20220017561Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: ApplicationFiled: July 1, 2021Publication date: January 20, 2022Applicant: KAYLA THERAPEUTICSInventors: Fabienne VERNEJOUL, Gerard TlRABY, Thierry LIOUX
-
Publication number: 20210353760Abstract: The present invention provides a Pro-cyclic dinucleotide (Pro-CDN) comprising a STING agonist cyclic dinucleotide which is coupled to a linker system. The Pro-CDNs of the present invention can be metabolized at a targeted site into CDNs and exert their full immunomodulatory effects at said targeted site. The present invention also provides conjugates wherein a Pro-CDN is conjugated to a Biologically Active Molecule (BAM) such as e.g. a cytotoxic molecule, a lipid, a protein, a peptide, a nucleic acid, a sugar or a PRR ligand. The invention provides also methods related to the use of such compounds to perform their activities at their targeted sites, to exert cytotoxic, cytostatic or immunomodulatory effects, to treat or to prevent diseases such as cancers, immunological disorders or infections.Type: ApplicationFiled: December 28, 2018Publication date: November 18, 2021Inventors: Thierry LIOUX, Fabienne VERNEJOUL, Cédric BOULARAN, Michèle TIRABY
-
Patent number: 11053272Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: GrantFiled: February 4, 2020Date of Patent: July 6, 2021Assignee: KAYLA THERAPEUTICSInventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
-
Publication number: 20200255469Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: ApplicationFiled: February 4, 2020Publication date: August 13, 2020Inventors: Fabienne VERNEJOUL, Gerard TIRABY, Thierry LIOUX
-
Patent number: 10562929Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: GrantFiled: June 12, 2018Date of Patent: February 18, 2020Assignee: KAYLA THERAPEUTICSInventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
-
Publication number: 20180354983Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: ApplicationFiled: June 12, 2018Publication date: December 13, 2018Inventors: Fabienne VERNEJOUL, Gerard TIRABY, Thierry LIOUX
-
Patent number: 10011630Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: GrantFiled: September 9, 2015Date of Patent: July 3, 2018Assignee: INVIVOGENInventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
-
Publication number: 20170340658Abstract: A kit of parts includes a) gemcitabine or a pharmaceutically acceptable salt thereof and b) a cyclic dinucleotide or pharmaceutically acceptable salt thereof, wherein the cyclic dinucleotide or pharmaceutically acceptable salt thereof is an agonist of the receptor known as “stimulator of interferon genes” (STING), for use in the treatment of solid pancreatic cancer.Type: ApplicationFiled: December 9, 2015Publication date: November 30, 2017Inventors: Fabienne VERNEJOUL, Daniel DROCOURT, Jesus ROMO, Gerard TIRABY, Thierry LIOUX
-
Patent number: 9567336Abstract: A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.Type: GrantFiled: March 15, 2013Date of Patent: February 14, 2017Assignee: INVIVOGENInventors: Fabienne Vernejoul, Arnaud Debin, Daniel Drocourt, Eric Perouzel, Gerard Tiraby, Thierry Lioux
-
Publication number: 20160362441Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.Type: ApplicationFiled: September 9, 2015Publication date: December 15, 2016Inventors: Fabienne VERNEJOUL, Gerard TIRABY, Thierry LIOUX
-
Patent number: 9458184Abstract: A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the conjugated compound and a polyanionic molecule and a pharmaceutical composition containing the conjugated compound or complex. Also described is the use of the conjugated compound or complex in the treatment of infection, cancer or immune disorders or for use in vaccines.Type: GrantFiled: March 15, 2013Date of Patent: October 4, 2016Assignee: INVIVOGENInventors: Fabienne Vernejoul, Arnaud Debin, Daniel Drocourt, Eric Perouzel, Gerard Tiraby, Thierry Lioux
-
Patent number: 9364494Abstract: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.Type: GrantFiled: October 10, 2008Date of Patent: June 14, 2016Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), CaylaInventors: Louis Buscail, Gérard Tiraby, Fabienne Vernejoul, Christiane Susini, Daniel Drocourt
-
Patent number: 9295732Abstract: A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:Type: GrantFiled: February 22, 2013Date of Patent: March 29, 2016Assignee: INVIVOGENInventors: Thierry Lioux, Daniel Drocourt, Fabienne Vernejoul, Gerard Tiraby, Eric Perouzel
-
Publication number: 20150190480Abstract: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.Type: ApplicationFiled: January 2, 2015Publication date: July 9, 2015Inventors: LOUIS BUSCAIL, GERARD TIRABY, FABIENNE VERNEJOUL, CHRISTIANE SUSINI, DANIEL DROCOURT
-
Publication number: 20140242108Abstract: A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:Type: ApplicationFiled: February 22, 2013Publication date: August 28, 2014Applicant: CAYLAInventors: Thierry LIOUX, Daniel DROCOURT, Fabienne VERNEJOUL, Gerard TIRABY, Eric PEROUZEL